Interleukin-33 (IL-33) is a new member of the IL-1 cytokine family which plays roles in the nucleus as a nuclear factor and is released by damaged or necrotic cells to act as a cytokine. It can be released via damaged or necrotic cells and functions as a cytokine. The released IL-33 activates the downstream NF-κB and MAPKs signaling pathways through the isomers of the specific receptor ST2 and the interleukin-1 receptor accessory protein (IL-1RAcP), resulting in danger signals and the activated multiple immune responses. IL-33 is abnormally expressed in various tumors and involves in tumorigenesis, development, and metastasis. Moreover, IL-33 can play both pro-tumor and anti-tumor roles in the same type of tumor.

白细胞介素-33(interleukin-33，IL-33)是IL-1家族的一位新成员，其不仅可以在细胞核内作为核因子发挥作用，也可以被损伤或坏死的细胞释放到细胞外作为细胞因子发挥作用。被释放的IL-33通过由特异性受体肿瘤发生抑制子2(suppression of tumorigenicity 2，ST2)及IL-1受体辅助蛋白(interleukin 1 receptor auxiliary protein，IL-1RAcP)组成的异构体激活下游的NF-κB和MAPKs信号通路，进一步激活多种免疫反应。IL-33在多种肿瘤(如肺癌、乳腺癌、结直肠癌等)中异常表达，参与肿瘤的发生、发展和转移，甚至在同一类肿瘤中同时发挥促肿瘤和抗肿瘤的双重作用。.

Keywords: interleukin-33; suppression of tumorigenicity 2; tumor; tumor microenvironment.